These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 25962349

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.
    Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, Massocco A, Manfrin E, Pegoraro C, Zamboni G.
    Virchows Arch; 2011 Jul; 459(1):1-10. PubMed ID: 21643691
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
    Ge QD, Lv N, Kong YN, Xie XH, He N, Xie XM, Wei WD.
    Asian Pac J Cancer Prev; 2012 Jul; 13(10):5081-6. PubMed ID: 23244114
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO.
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
    Chen X, Fan Y, Xu B.
    Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Nishimiya H, Kosaka Y, Yamashita K, Minatani N, Kikuchi M, Ema A, Nakamura K, Waraya M, Sengoku N, Tanino H, Kuranami M, Watanabe M.
    Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
    [Abstract] [Full Text] [Related]

  • 39. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
    Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, Mazzarol G, Ghisini R, Mazza M, Iorfida M, Rotmensz N, Veronesi P, Luini A, Goldhirsch A, Colleoni M.
    Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
    [Abstract] [Full Text] [Related]

  • 40. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
    Ogiya A, Kimura K, Nakashima E, Sakai T, Miyagi Y, Iijima K, Morizono H, Makita M, Horii R, Akiyama F, Iwase T.
    Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.